Sterling Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Sterling Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$45.5K	Buy	269 +1	+0.4%	+$173	﹤0.01%	1678
2025 Q4	$48.9K	Buy	268 +170	+173%	+$23.7K	﹤0.01%	1812
2025 Q3	$11.9K	Hold	98	–	–	﹤0.01%	2393
2025 Q2	$10.2K	Buy	98 +60	+158%	+$6.35K	﹤0.01%	2121
2025 Q1	$4.43K	Buy	38 +1	+3%	+$114	﹤0.01%	2231
2024 Q4	$3.13K	Hold	37	–	–	﹤0.01%	2637
2024 Q3	$3.33K	Buy	+37	New	+$3.23K	﹤0.01%	1940

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sterling Capital Management's AXSM Position: Q1 2026 in Review

Sterling Capital Management increased its Axsome Therapeutics (AXSM) stake by 0.37% in Q1 2026, buying an estimated $173 and bringing the position to 269 shares worth $45.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1678.

Sterling Capital Management first reported a position in AXSM in Q3 2024 and has held it in 7 quarters since. The position peaked at $48.9K in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

Sterling Capital Management held 269 shares of Axsome Therapeutics worth $45.5K as of Q1 2026.
Sterling Capital Management bought 1 Axsome Therapeutics share in Q1 2026, an estimated $173.
Axsome Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q1 2026, its #1678 holding.
Sterling Capital Management first reported a position in Axsome Therapeutics in Q3 2024 and has held it in 7 quarters since.
Sterling Capital Management's Axsome Therapeutics position peaked at $48.9K in Q4 2025.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Sterling Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.